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O presente relatório tem como objetivo descrever as atividades desenvolvidas 
no âmbito do estágio curricular na área dos assuntos regulamentares, que 
decorreu entre 1 de Agosto de 2011 e 4 de Maio de 2012, no Departamento de 
Manutenção do Mercado da Phagecon – Serviços e Consultoria Farmacêutica, 
Lda.. Este estágio é parte integrante do programa de formação do mestrado 
em Biomedicina Farmacêutica e teve como principais objetivos a aquisição de 
experiência na realização das atividades comumente associadas aos assuntos 
regulamentares, bem como a consolidação de conhecimentos e o 
desenvolvimento de novas competências técnicas.  
O primeiro capítulo introduz o estágio curricular em assuntos regulamentares, 
seguindo-se uma descrição generalista do contexto regulamentar aplicável às 
atividades realizadas. Os capítulos e secções posteriores destinam-se a 
descrever a empresa que proporcionou o estágio, os objetivos para este 
definidos e as atividades e tarefas desempenhadas. Por último, será feita uma 
discussão crítica do estágio, incluído a análise das principais dificuldades 
sentidas e as competências adquiridas. 
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abstract 
 
This report aims to describe the activities performed during the curricular 
internship in regulatory affairs, which took place from August 1, 2011 to May 4, 
2012 at Marketing Maintenance Department of Phagecon – Serviços e 
Consultoria Farmacêutica, Lda.. The internship is an essential part of the 
training programme in Pharmaceutical Biomedicine and it main goals were: to 
gain experience in conducting common regulatory activities; to consolidate 
background knowledge and to develop new technical skills. 
The first chapter introduces the internship and is followed by a general 
description of the regulatory environment applicable to the activities performed. 
The later chapters and respective sections intend to: describe the hosting 
company, define internship goals and give a detailed description of the 
activities and tasks performed during this 9 months experience. Finally, it will 
be presented a critical discussion of internship outcomes, including the analysis 
of the main difficulties and key competences acquired.   
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The Training Programme in Pharmaceutical Biomedicine offers its students the 
opportunity to make a curricular internship during the second curricular year. I 
decided to make the curricular internship in the field of regulatory affairs (RA), 
because I wanted to put into practice and to test all the competences developed 
during Biomedical Sciences degree and the first year of this master.  
The internship as a RA officer took place in Coimbra, at Phagecon – Serviços e 
Consultoria Farmacêutica, Lda., more specifically at Marketing Maintenance 
Department (MMD), responsible for all the projects related to the post-marketing 
phase of medicines, cosmetics, medical devices and biocide products. It was 
predicted to start at September 1, 2011 and finish at May 31, 2012 (9 month 
duration). However, due to outsourcing processes, paternity leaves and holidays, it 
was suggested to start 1 month earlier. Thus, the internship began at August 1, 
2011 and finished at May 4, 2012. During the complete internship period I 
respected the regular working period, (9 AM to 6 PM) under the supervision of 
Ricardo Andrade, MMD’s coordinator. 
The first chapter of this report is dedicated to the hosting company 
characterization, including foundation history, internal organization and general 
working methods. After that it is possible to find a comprehensive description of all 
the activities and tasks assigned and concluded during the 9 months internship. 
This description is organized in 2 main sections: transdisciplinary experience and 
monodisciplinary experience. For each activity or project type it will be presented: 
a legal and regulatory introduction, the general procedures that are usually 
undertaken and, finally, my personal experience, the knowledge acquired and 
main difficulties felted.  
The last chapter is dedicated to the discussion of the entire experience and to the 
over whole balance of the 9 months internship experience.  
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State of Art 
Medicines are an essential tool in the field of healthcare and hold particular 
importance for society, since they have contributing to the improvement of several 
health indicators during the latest decades, such as the increase of life expectancy 
and quality of life, or even the decrease of morbidity. Through the development, 
manufacturing and marketing of medicines, pharmaceutical industry also 
contributes largely for local economies growth and development (1, 2). 
Despite the undeniable benefits of medicines, they can also present several risks 
which can lead to persistent disabilities or even death, like it happened with 
thalidomide in the 1960s. Unfortunately, due to this drastic events associated to 
medicines exposure it was mandatory to develop pharmaceutical legislation in 
order to implement control mechanisms intended to minimize and mitigate 
medicines’ risks (3). In this context, pharmaceutical legislation major goals are the 
protection of public health by promoting measures that enhance medicines’ safety, 
quality and efficacy. To accomplish this objective, pharmaceutical legislation it 
continuously under change in order to respond to new challenges or problems 
previously not identified. New legislation can also be developed to simplify the 
current legal status making it more clear and easy to understand, or even as part 
of the process of adaption to science’s advances (4).  
For several decades, each country developed its own laws and regulations, which 
differ largely from country to country, leading to a very heterogenic and complex 
legislative framework. These differences turned out into global trading difficulties, 
at the same time pharmaceutical industry became more international and sought 
worldwide expansion. The obligation to respect different requirements leads very 
often to tasks duplication and consequently to unnecessary time and money 
consumption (5). 
In this context, it was urgent to standardize procedures and requirements. This 
was first initiated in 1980s by the European Community, as an attempt to establish 
unique requirements across the member states, allowing creating a unique and 
internal market for pharmaceuticals. This same objective is maintained in the 
current perspective of European Union (EU), which efforts on harmonization are 
not just focused on medicines, but also on biocides or cosmetic products.  
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It was also established a central authority, European Medicines Agency (EMA), 
which coordinates the scientific resources available for evaluation and supervision 
of medical products, giving advice and support national competent authorities 
(NCA). In Portugal, INFARMED, I.P. is the responsible entity for manage all 
national activities related to human medicines, medical devices and cosmetic 
products. On the other hand, Direcção-Geral de Veterinária (DGV) is responsible 
for veterinary medicinal products (VMP). 
Later on, during 1990, the positive results of European effort for harmonization 
contributed to the establishment of a new entity dedicated to work on international 
harmonization on pharmaceuticals requirements for registration, the International 
Conference on Harmonization (ICH). ICH is constituted by members of industry 
and regulatory authorities from Europe, United States of America and Japan, who 
work together on the development of guidelines and recommendations, which will 
then be implemented on each region. Other entities with interest on ICH activities 
had been invited to participate as observers (5). 
The greatest achievements of ICH, such as the harmonization of Marketing 
Authorization (MA) request contents (presented below), are the result of scientific 
consensus between industry and regulatory entities and the commitment to 
implement and to respect the final guidance (5). 
The ultimate result of legislation harmonization procedures is the currently highly 
regulated environment for medicines, since their early phase of development up to 
post-marketing phase, embracing the entire medicines’ lifecycle.  
 
Medicines’ Lifecycle 
The development of new and innovate medicines represents the ultimate goal of 
research and development (R&D) activities developed by pharmaceutical industry. 
R&D projects for the development of innovative medicines are extremely long (10 
to 15 years), expensive (between 800 million dollars and a 1 billion dollars), 
complex and risky (1). Thus, R&D of medicines presents several challenges for 
pharmaceutical industry, which ends up contributing to the extremely high level of 
competitiveness among different companies.  
University of Aveiro 
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The R&D of a new medicine first takes place with the search for molecules that 
may have a positive pharmacologic effect in the human body. After optimization of 
these molecules, the R&D process moves on to non-clinical studies, in order to 
obtain safety, pharmacologic and pharmacokinetic information. The evaluation of 
the collected information regarding its implication on human subjects will 
determine whether or not human trials should be performed. Thus, if non-clinical 
results reveal potential positive results in humans, the molecule will advance in 
R&D process to clinical studies. Each clinical study will be specifically designed to 
answer a well-defined and relevant question and should respect all the applicable 
legislation and requirements. Clinical trials can be classified accordingly to the 
time they occur during clinical developed or by their objectives. Clinical trials are 
typically divided in 4 phases:  
 Phase I – usually performed in a small number of healthy volunteers, these 
studies intend to better define the medicine’s safety profile in humans. The 
most common type of studies is human pharmacology studies, which 
objectives may include to: assess tolerance, describe pharmacokinetics and 
drug metabolism. 
 Phase II – developed with a relatively small number of patients, usually 
without further complications associated. Therapeutic exploratory studies 
are the most commonly performed during this phase, their principal 
objectives are to: describe the relationship between dose and physiological 
answer and estimate the optimal doses that should be used in next studies, 
as well as endpoints and methodologies.  
 Phase III – involves large groups of patients, so that it is possible to confirm 
medicine’s efficacy and to better define its safety profile. It is essential that 
these therapeutic confirmatory studies provide all the needed information to 
determine a positive benefit-risk balance, essential to obtain MA approval.  
 Phase IV – it takes place after MA is granted and it intends to evaluate the 
therapeutic use of medicine in common clinical practice, which is a far less 
controlled environment than clinical trials. Through phase IV studies it will 
be possible to: complete medicine’s safety and efficacy profiles or identify 
rare adverse drug reactions (ADR) (1, 6). 
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Nevertheless it is important to take in consideration that this temporal division of 
clinical trials does not defines the order in which studies are performed, since 
certain kind of studies may be developed in several phases, as depicted from 
figure 1 (6). 
 
 
Figure 1 – Relationship between clinical development phases and type of studies, reproduced from 
reference (6) 
 
 
As mentioned at the end of phase III, the pharmaceutical company developing the 
medicine expects to have collected all necessary information on safety and 
efficacy to prove medicine’s positive risk-benefit relationship.  
However, before any new medicine can be introduced on the European market it 
has to have a valid MA, granted by a competent authority. At this point it is crucial 
to define the regulatory strategy for MA request preparation and submission. 
There are different procedures to request a MA, namely: 
 Centralized Procedure (CP). MA request is submitted to EMA and 
evaluated by experts’ committees. If granted the MA will be valid in all EU 
member states.  
 Decentralized Procedure (DCP). The applicant will submit the MA request 
simultaneously in several EU member states, to the respective NCAs. One 
of the member states will be appointed as the reference member state and 
will be responsible by the detailed analysis of the request and the 
elaboration of the report. This report will then be evaluated by the other 
NCA. This procedure is possible only if there is no MA in any of the EU 
member states. 
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 Mutual Recognition Procedure (MRP). The process is similar to DCP, 
however there is an initial MA request to a single member state NCA. After 
MA is granted it is requested to other member states NCAs to recognize the 
MA on their own countries.  
 National Procedure. This process is used when the applicant intends to 
request a MA valid in a single country. The authority responsible for the 
evaluation will be the NCA of the concern member state.  
 
Independently from the procedure chosen, MA request is submitted together with 
the MA dossier, which has a well-defined structure and organization, commonly 
noun as Common Technical Document (CTD). CTD is one of the many 
harmonization products of ICH and it became mandatory for new MA requests 
submitted to Europe and Japan competent authorities, being strongly 
recommended by USA competent authority (Food and Drug Administration – 
FDA). Figure 2 shows CTD structure and organization (7).  
 
Figure 2 – Common Technical Document Organization, reproduced from reference (7) 
 
Despite the fact that Module 1 is specific for each region, including the specific MA 
request form or proposed product information texts. The other 4 modules should 
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be common to the 3 regions. This brings great advantage for pharmaceutical 
industry, since it allows preparing a single dossier regarding medicine’s safety, 
efficacy and quality for different world regions, which ultimately saves time, 
resources and money (7).  
Additionally, documents and information included on each CTD´s modules should 
respect the dispositions of the latest versions of ICH guidelines regarding this 
subject, namely:  
 M4 (R3): Organisation of the common technical document for the 
registration of pharmaceuticals for human use. 
 M4Q (R1): The common technical document for the registration of 
pharmaceuticals for human use: quality. 
 M4S (R2): The common technical document for the registration of 
pharmaceuticals for human use: safety. 
 M4E (R1): The common technical document for the registration of 
pharmaceuticals for human use: efficacy. 
 
At European level, and as trend of harmonization within EU, some documents 
presented on CTD should also follow defined templates. It is the case of product 
information texts, which includes Summary of Product Characteristics (SmPC), 
Package Leaflet (PL) and labelling. Product information templates and contents 
are defined by the Working Group on Quality Review of Documents (QRD), an 
experts group of EMA (8). QRD latest versions are available at EMA’s website in 
word format and in all EU languages, so that they can be easily used.  
The terms used on product information texts should be in accordance with Medical 
Dictionary for Regulatory Activities (MedDRA) and with the list of standard terms 
defined by the European Directorate for the Quality of Medicines & HealthCare 
(EDQM) (8).  
Although obtaining MA for a new medicine is an unquestionable measure of 
success after years of work and effort, it does not mean that all activities 
concerning that medicine are finished. In fact, it is quite the opposite, since in this 
new phase of medicine’s lifecycle new information can come up at any time and it 
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will be necessary to maintain MA dossier updated, through regulatory procedures 
defined in legislation, noun as MA variations. In practical terms, MA variations 
represent changes to the initially approved information, thus they should be 
submitted to the competent authorities.  
If the Marketing Authorisation Holder (MAH) has the intention to maintain the 
medicine on the market, the MA needs to be renewed. In this circumstance, a MA 
renewal request should be submitted to competent authorities, so that they can 
ensure that the benefit-risk balance remains positive.  
 
Regulatory Affairs 
RA professionals play important roles at each step of products’ lifecycle, from their 
early development phase through post-marketing activities. They will be the 
responsible for ensuring compliance to the applicable regulatory framework, which 
demands for an extensive technical knowledge and expertise, under continuous 
development and updating. 
RA professionals have multidisciplinary knowledge and their areas of expertise 
embrace science, law and business. They can work in different entities, namely 
pharmaceutical industry, government agencies, competent authorities and contract 
research organization (CRO) (4). 
From industry and CRO perspectives, RA professionals may be responsible for: 
 Collect and organize all the information and documents required for 
medicines’ MA request or biocides, cosmetic products or medical devices 
registration processes. 
 Identify the need of medicines’ MA variations, prepare and submit those 
accordingly to the applicable legislations. 
 Give technical support to company’s regulatory strategy definition. 
 Make a regular review of new legislation, both under preparation and 
already implemented. 
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The efficient performance of these activities is essential to decrease competent 
authorities’ evaluation timing, contributing to save human and financial resources, 
and to faster provide quality products to general population. Simultaneously it is 
possible to avoid sanctions for non-compliance with applicable regulations.  
The absolute respect for legislation dispositions will ultimately contribute to the 
recognition of the company’s high quality standards, not just by general public and 
regulatory authorities, but also by competitors and potential clients, in CRO’s 
perspective.  
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Internship Goals 
At the time my internship at Phagecon began, I had no practical experience on RA 
activities, despite having the basic science and regulatory knowledge.  
In this context, the following goals, to be achieved until the end of my internship, 
were established: 
 Develop depth knowledge on RA and medicines legal framework. 
 Become familiarized with the real standards and procedures of RA most 
common activities, which should be respected in order to obtain regulatory 
approvals. 
 Be able to think analytically and critically analyse new legislation and its 
potential impact on current regulatory practice. 
 Strengthen personal skills such as organization and communication. 
 Be capable of handle several tasks and projects simultaneously and 
prioritize them. 
 Efficiently manage deadlines. 
 Contribute to Phagecon’s internal objectives and success. 
 
In short, the internship goals can be resumed to the acquisition of professional 
experience within the field of RA and the development of new skills that can bring 
competitive advantages in the job market.  
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Host Company Presentation 
Phagecon – Serviços e Consultoria Farmacêutica, Lda. is a portuguese CRO, 
founded in January 2006, which is dedicated to provide quality services to 
pharmaceutical industry within the scope of regulatory, medical and scientific 
affairs and pharmacovigilance.  
Phagecon is part of a large “group” of companies, including: 
 FHC Farmacêutica, Lda.. Founded in 1998 with objectives focused on 
exportation of pharmaceutical products. Currently it remains dedicated to 
the international management distribution and logistics, operating in several 
countries of Europe, Africa, Middle-East and Latin America (9).  
 Empipharma. Located in Coimbra and was also founded in 1998, it is 
dedicated to storage and distribution of pharmaceutical products within 
Portugal. Empipharma core business is the wholesale and pre-wholesale 
activity in Portugal (9). 
 Overpharma – Produtos Médicos e Farmacêuticos, Lda.. Was founded in 
2001, with location in Lisbon, and it is dedicated to hospital market 
wholesaler in Portugal. Currently presents a large portfolio of disposable 
materials, medical devices and some medicines (9). 
 Laboratórios Basi – Indústria Farmacêutica, S.A.. Acquired in 2007 to 
establish a brand in pharmaceutical market, both national and international. 
Basi is dedicated to the manufacturing, galenic development and licensing 
of several medicines with different pharmaceutical forms (9). 
 Zeone – Informática, Lda.. Founded in 2008, it offers technic consulting 
services in IT field, such as software development, web design or 
informatics assistance (9). In this context it also gives informatics support to 
all companies of the “group”.  
 Paracélsia. The takeover took place in 2011; it is dedicated to the 
manufacturing of large volume parenteral solutions (9).   
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At the foundation date, the main Phagecon’s clients were the companies from the 
“group”. As a result of Phagecon’s establishment in the CRO portuguese market, 
currently there is a large percentage of external clients. 
Phagecon presents a wide range of services to its national and international 
clients. The services’ portfolio is constantly being adapted to better respond to the 
ever-changing market requests and demands. As a result, new services can 
always be developed and added to those presented on table 1. 
 
Table 1 - List of Phagecon's services organized by specialization area, adapted from reference (10) 
 
 
Specialization Area Scope of Action 
Regulatory Affairs 
Medicines  
Medical Devices 
Cosmetics and Personal Hygiene 
Products 
Food Supplements 
Biocides 
Pharmaceutical Affairs 
Quality Management Systems  
Good Manufacturing Practices 
Good Laboratorial Practices 
Auditing 
Safety, Hygiene and Health at Work  
Scientific Affairs 
Expert Reports 
Advertisement and Promotional 
Materials 
Technical Translations 
Pharmacovigilance 
Local Representation 
Pharmacovigilance  
Pharmacovigilance Systems 
(development and implementation) 
Periodic Scientific Literature 
Screening  
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Periodic Safety Update Reports  
Typed II Safety Variations 
Risk Management Systems 
(development and implementation) 
Surveillance of Medical Devices and 
Cosmetics 
 
In August 2011, Phagecon had a 12 full-time employees team, distributed for 
several departments accordingly to their area of expertise, and experts contacted 
occasionally within specific projects to perform periodic tasks. The organogram 
shown in figure 3 identifies the several departments and their hierarchic 
relationship.  
 
 
Figure 3 – Phagecon's Organogram, adapted from reference (10) 
 
During 2010 Phagecon gained the certification for its Quality Management System 
(QMS), from the multinational Bureau Veritas. Through this process Phagecon 
assumed an internal and external commitment of high level and quality in all 
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process developed at the company. A certificated management system brings 
great benefits since it enhances efficacy of all tasks developed, at the same time it 
promotes the recognition and trust of current and future clients.  
QMS is described in detail at QMS manual, which is a core document to 
understand QMS principles and their implications on the performance of daily 
tasks. In this context, I was given training on this topic, which contents will be 
described on the further sections of this report.  
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ON-THE-JOB TRAINING IN 
REGULATORY AFFAIRS 
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The present chapter of this report intends to describe in detail all the activities and 
tasks developed during the curricular internship at Phagecon. It is organized in 2 
main sections: the transdisciplinary experience and the monodisciplinary 
experience.  
The first will describe the coaching events which learning outcomes were essential 
to the performance of several projects tasks, accordingly to Phagecon’s 
established processes. In this perspective, these learning outcomes were present 
in all the activities performed, in other words, they are relevant to the complete 
internship. 
On the other hand, the monodisciplinary experience section describes the specific 
activities or tasks performed during the major part of the internship, presenting a 
detailed description to each one.   
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Transdisciplinary Experience 
This section is intended to describe the learning outcomes of all coaching events 
which I had the opportunity to participate during the internship. Their learning 
outcomes were put into practice during the performance of several activities and 
tasks assigned during the internship and were essential to achieve success.  
The training events I attended to during this internship were subordinated to the 
following themes: general presentation of Phagecon’s QMS; operational principals 
of project manager software and basic pharmacovigilance concepts. A detailed 
outline of each theme is given below.  
 
Phagecon’s Quality Management System 
Besides the deep knowledge of the several experts working at Phagecon, the 
quality of services provided to clients is also ensured by a certificated QMS.  
QMS is described in detail at QMS manual, which is a living document suffering 
changes whenever considered important to fit company’s necessities and goals. 
I was first introduced to QMS at time internship began and refresh sessions were 
done every time a new version was launched and as a preparation to the Bureau 
Veritas annual audit.  
Currently QMS is on the 4th Edition, dated March 3, 2012 and it is a central 
document that identifies Phagecon’s daily tasks and their interactions, disclosures 
responsibilities and clearly states the company’s goals for the future, i.e. 
company’s vision - “being a company with financial stability and globally 
recognized by its competence” (10).  
QMS manual also establishes Phagecon’s mission, i.e. the roadmap for achieving 
the defined goals, as following: “contribute for the pharmaceutical sector success, 
especially regarding pharmaceutical industry and distribution activities, through the 
presentation of services of their interest, which are innovative, personalized and 
executed by a group of specialized collaborators who guarantee the quality of the 
services” (10). 
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Everyday Phagecon’s team works to achieve the established goals, trough the 
execution of several tasks, each one of these belonging to one of the following 
nine processes (group of activities) (10): 
1. Define strategy. 
2. Resources supply. 
3. Market analysis. 
4. Services development. 
5. Answer to possible clients contact. 
6. Plan the project. 
7. Support project’s execution. 
8. Project execution. 
9. Evaluate and improve outputs. 
These nine processes are applicable to the different departments and they do not 
take place exactly on this order, since they can interact with each other as 
presented on figure 4.  
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Figure 4 – Relationship of Phagecon´s quality defined processes, adapted from reference (10) 
 
The processes within the delimitation line correspond to the activities that take 
place frequently in order to complete the services offered. On the other hand, the 
processes placed outside the delimitation line are dedicated to the evaluation and 
support of QMS. 
Identifying and studying the processes occurring at Phagecon and their 
interactions allow defining the best strategy to deliver the main outcome: high 
quality services personalized to each client needs. As a consequence of new 
strategies implementation, QMS will be under continuous improvement and 
company’s efficacy will be sequentially higher (10). 
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A highly organized and effective QMS requires control over the documents 
generated within its scope, in other words it requires a structured documental 
management system. In Phagecon’s QMS different document types are organized 
hierarchically, from the most general to the most detailed as following (10):  
1. QMS manual. 
2. Processes Forms (PFs). 
3. Written Procedures (WPs).  
4. Work Instructions (WIs). 
5. Register Documents (RDs).  
 
Each one of the 9 processes previously identified has its own PF, which globally 
describes the activities taken and identifies the responsible collaborator.  
For the purpose of this internship, the activities I developed belonged mostly to the 
processes number 7 (project plan) and 9 (project execution). In this context, PF 
number 7 and 9 were important documents for me to get familiarized with the 
general tasks that should be performed for each project and their correct 
sequence.  
On the other hand, both WPs and WIs describe activities executed at Phagecon, 
present the sequence of operations to be performed for specific projects and 
activities (10). The lecture of these documents previously to the initiation of certain 
project types was useful, since they gave me a comprehensive description of all 
steps to be performed.  
Finally the RDs result from the execution and implementation of QMS and include 
registration forms, plans, general templates, lists, among others.  
 
 
Project Manager Software - Online Tool 
An important tool that helps the execution of some QMS processes, such as 
planning or executing, is the online Project Manager Software (PMS).  
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PMS is accessed through the restricted area of Phagecon’s website and it displays 
all the closed out and on-going projects.  
Each project has a cover page with a simply description and the identification of 
the client, the Phagecon´s responsible manager and the project charged value.  
There is another project specific page, dedicated to planning and execution, where 
the responsible manager is able to define the tasks that should be performed, its 
deadlines and responsible persons for execution and revision. After project plan is 
complete, it is submitted for department coordinator revision. At this point project 
manager software will block the project and no more tasks can be introduced or 
even updated, until the project is approved. In my particular situation MMD’s 
coordinator was the responsible collaborator to create my new projects on project 
manager software and to approve my planning for each one of those.  
After project approval, and as it progresses, each task shall be updated with the 
amount of time spent every day until its conclusion, as well as any relevant 
information (whenever applicable).  
Since I was responsible for several projects, the initial coaching on the 
functionalities of this online tool was essential for me to complete all the fields 
properly, including the initial planning and daily updates.  
As a result of these functionalities, online PMS enables project manager or 
department’s coordinators to close monitoring the projects in real time, enhancing 
productivity and efficacy. 
On the other hand, online PMS also gives top management the opportunity to 
evaluate the productivity of each employee by the analyses of daily reports 
containing all the tasks introduced in the different projects, in a certain day. Initially 
I was asked to print the daily report and archive it in the proper dossier, to be 
evaluated by the executive director. However, technological innovations applied to 
the initial PMS lead daily reports to be directly sent to executive director’s e-mail, 
at the end of each working day.  
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Pharmacovigilance – Basic Concepts 
As previously indicated, Phagecon offers pharmacovigilance services to several 
clients. In this context, everyone working at Phagecon must have basic 
pharmacovigilance knowledge in case it is necessary to record an ADR 
spontaneous notification.         
This basic knowledge was transmitted to me in simple training event, followed by a 
quick quiz. Most of the topics discussed were in accordance with the knowledge 
acquired during the biomedical science degree and pharmaceutical biomedicine 
master, including:  
 Pharmacovigilance history. 
 ADR definition. 
 Pharmacovigilance importance and goals. 
 Difference between ADR and adverse event. 
 ADR spontaneous notification advantages and disadvantages. 
 
The last point discussed constituted new information to me, since it was related to 
the essential information to be collected during an ADR spontaneous notification. 
Thus in case I received any type of communication (phone call, e-mail, letter or 
personal) regarding an ADR of a client’s product, I should collect, at least, the 
following information: 
 Name and contact of the person who is notifying. 
 Description of the suspected ADR. 
 Medicine suspected of causing the ADR. 
 Patient identification. 
During the 9 months internship I never had to put in practice the knowledge 
reviewed and acquired during this training event.  
University of Aveiro 
Health Sciences Department 
 
Curricular Internship Report   29 
Raquel Pinela 
Monodisciplinary Experience 
As the title indicates this section is dedicated to the individual activities on which I 
participated during the internship. Each type of activity took place at a defined 
moment, but it was usually repeated several times, within the scope of similar 
project types.  
Activities’ description is organized by product type. Thus, there will be 2 main 
subsections: the first is related to human medicines and the second to VMPs. 
 
 
Human Medicines 
The latest legislation defines medicinal product as: 
“Any substance or combination of substances presented as having properties for 
treating or preventing disease in human beings;  
or 
Any substance or combination of substances which may be used in or 
administered to human beings either with a view to restoring, correcting or 
modifying physiological functions by exerting a pharmacological, immunological or 
metabolic action, or to making a medical diagnosis” (11). 
This subsection gives details on the human medicine related activities performed 
during the internship, including: MA variations, transfers and renewals and also 
multilingual notifications for labelling and package leaflets.  
 
 
Marketing Authorisation Variations 
During medicines’ life cycle MAH may need to adjust or amend the information 
submitted at the time of MA request, in order to: update productions methods to 
current technologies; undertake changes demanded by competent authorities, like 
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INFARMED, I.P.; or even to bring up to date manufacturers chain, among many 
others possibilities.  
MA variations can be classified as major or minor accordingly to its: 
 Impact on the already approved information. 
 Potential risk to public health. 
 Possible impact on medicine’s quality, safety and efficacy. 
 
Similarly to other RA activities, MA variations are highly regulated by european 
and national legislations. From August 2011 to April 2012 the legislation applicable 
to MA granted by centralized, decentralized or mutual recognition processes 
should follow the disposition of Regulation (EC) No 1234/2008 of 24 November 
2008. On the contrary, nationally authorized products (MA conceded by 
INFARMED, I.P., valid for portuguese territory only), should respect the national 
law, particularly the Decreto-Lei n.º 176/2006, de 30 de Agosto (12).  
For future reference, it is important to take in consideration that a new European 
Regulation concerning MA variations was recently published. Regulation (EC) No 
712/2012 of 3 August 2012 introduces several changes to the previous regulation, 
including the extension of its scope to MA variations of medicines nationally 
authorized. In Portugal, the application of the new regulation to nationally 
approved medicines will came into force from August 4, 2013 (13).  
Hereupon, and considering that all MA variations projects I undertake during the 
internship were related to nationally authorized medicines, all the procedures 
described are referent to the applicable legislation at that time (Decreto-Lei n.º 
176/2006, de 30 de Agosto).  
Accordingly to portuguese applicable legislation, MA variations can be classified 
as: 
 Type IA. 
 Type IB. 
 Type II. 
 Transfer of MA. 
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Further details on each one of these MA variations, including the regulatory 
procedures to be respected, the major learning and also difficulties felts while 
developing this kind of projects, are presented on the following pages. 
 
Type I Variations 
Overall Requirements 
Type I variations correspond to those with the lowest risk regarding medicines’ 
safety, efficacy or quality. The accepted type I variations are listed at the guidance 
note “Guideline on dossier requirements for Type IA and IB notifications” (14). This 
guidance also encompasses, for each variation, the conditions that must be 
satisfied as well as the list of documentation to be submitted, including the relevant 
parts of MA dossier that should be updated. For each variation, the guidance also 
specifies the variation type in IA or IB and assigns an identification number (14). 
All the information is displayed in a simple manner by the use of tables, as 
depicted from the excerpt presented on figure 5. 
 
 
Figure 5 – Example from European guidance regarding type I variations classification and 
requirements, reproduced from reference (14) 
 
Despite the fact that different type I variations may have specific and unique 
documentation to be submitted, as identified in the referred guidance note, there is 
a board-spectrum set of documentation which is generally requested 
independently the variation to be submitted. In this context, for each MA variation 
project I was involved in I had to prepare the following set of documents (15): 
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 MA dossier sections modified as consequence of variation. 
 Proof of payment of applicable fees and the corresponding guide of 
payment duly completed. 
 Identification of other MA variations already presented or to be presented in 
a near future, related to the same MA.  
 Reviewed SmPC, PL and labelling versions (whenever the variation implies 
changes in product information texts). 
Generally type I variations are intentionally undertaken by MAH, concerning 
company’s regulatory, manufacturing or marketing strategies. However, there is a 
particular type I variation that is a consequence of referral procedures, which on its 
turn result from an EC Decision, becoming mandatory in all EU countries (16, 17). 
Referral procedures may be invoked by the EC, any member state or any 
company that markets the medicine in matter, under well-established 
circumstances, which conducts to different referral types. INFARMED, I.P.’s 
nationally authorized generic products are most commonly affected by 2 types of 
referrals (16, 18):  
 Divergent decision referral – when it is identified a need of harmonization of 
national competent authorities’ decisions concerning the authorization, 
suspension or withdrawn of a certain medicine, as established by article 30 
of directive 2001/83/EC. There are examples of harmonization needs 
across European Union the authorization of different indications or posology 
for the same medicine or similar medicines (reference and generics). 
 Community interest referral – if public health protection measures are 
considered necessary, as a consequence of newly identified concerns 
related to the quality, safety or efficacy of a certain medicine or class of 
medicines, as established by article 31 of directive 2001/83/EC. 
 
After the initiation of the referral procedure, the question under study will be 
analysed by EMA’s specialized committees, usually Committee for Human 
Medicinal Products (CHMP) or Pharmacovigilance Risk Assessment Committee 
(PRAC), if the issue is related to medicines’ safety. The final recommendations for 
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a certain medicine or class of medicines follow an established format, which 
includes: 
 Opinion page, which presents the referral scope and legal basis.  
 Annex I, listing of all medical products affected by the referral, organized by 
member state and including for each medical product the invented name, 
MAH and approved strengths, pharmaceutical forms and route of 
administration. An example of EC recommendation annex I can be 
analysed in figure 6. 
 Annex II, which presents the reasons and conclusions leading to the 
recommendation made.  
 Annex III, that represents the english harmonized proposal for SmPC, PL 
and labelling that will have to be implemented by all MAH which medicines 
are affected by referral procedure (18). An example of EC recommendation 
annex III can be analysed in figure 7. 
 
 
 
Figure 6 – Example of EC Recommendation Annex I, adapted from reference (19) 
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Figure 7 – Example of EC Recommendation Annex III, adapted from reference (20) 
 
 
This recommendation is then evaluated and published by the EC. EC’s decision 
shall be implemented by all member states.  
In Portugal, INFARMED, I.P. will notify all MAHs, whose medicines are under the 
scope of EC decision, to submit product information texts accordingly. Deadline for 
submission is usually presented on the notification letter sent to MAHs.  
For generic medicines nationally authorized, product information texts should be 
prepared similarly to those published by the EC for the innovative medicine, in the 
relevant areas (21). In order to facilitate the text adaptation process, INFARMED, 
I.P., dedicated a section of its website to the presentation of all referral procedures 
which are already concluded and their respective decision annexes, including the 
portuguese version of the product information texts (22). The first look of this 
website can be observed in figure 8. 
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Figure 8 – INFARMED, I.P.'s online information regarding referral procedures, adapted from 
reference (22) 
 
 
Submission to INFARMED, I.P. 
Since September 2005 the submission of type I variations of nationally authorized 
medicines must be done electronically, through an INFARMED, I.P.’s website 
application (23).  
This online application has limited access to MAHs, since each one has an unique 
username and password, giving access to the all submission processes, both 
closed and under evaluation, of their authorized products.  
Every time I needed to access this application, I had to go to INFARMED, I.P.’s 
website and choose the option “Serviços Electrónicos”, under “Utilidades” on the 
left side menu, as it is highlighted in figure 9. 
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Figure 9 – INFARMED, I. P.'s online access to electronic services, adapted from INFARMED, I.P.’s 
website 
 
After left click on “Submissão electrónica de alterações” a new window opens and 
a login user and password are requested, as depicted from figure 10. These data 
are specific for each MAH, thus I needed to introduce the data accordingly to each 
client.  
 
 
Figure 10 – INFARMED, I.P. online login to type I variation electronic submission, adapted from 
INFARMED, I.P.’s website 
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Once the login is completed, I was able to search all the variations submitted to 
any of the concerned client medicines and obviously to submit new variations, as 
demonstrated by figure 11. 
 
Figure 11 – INFARMED, I.P.'s online application for type I variations electronic submission: cover 
page, reproduced from reference (24)  
 
Every time a new variation insertion starts a standard form, identical to the one 
presented in figure 12, has to be fulfilled regarding: 
 Medicines identification (name, dosage and pharmaceutical form).  
 Type of variation. 
 Information regarding the submission of other variations. 
 Goals of variation. 
 Contact details of the person responsible for the submission. 
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Figure 12 – INFARMED, I.P.'s online application for type I variations electronic submission: general 
form page, reproduced from reference (24) 
 
 
As a result of the variation type previously chosen a variation specific form will 
show up in the next step of variation submission, listing: 
 All the conditions that must be completed, so that MA can submit changes 
under the scope of type I variations. It is important to mention that all 
conditions must be confirmed, as a way to guarantee that they will not be 
neglected.  
 The entire set of documents essential to support MA variation. All 
documents must be uploaded with the corresponding designation.  
An example of this specific form is presented on figure 13. 
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Figure 13 – INFARMED, I.P.'s online application for type I variations electronic submission: 
example of variation’s specific form, reproduced from reference (24) 
 
For some variations, INFARMED, I.P. also requests the identification of the 
currently approved information versus the proposed information disposed in the 
tabular format of figure 14. 
 
 
Figure 14 – INFARMED, I.P.'s online application for type I variations electronic submission: specific 
form of currently approved versus the proposed information, reproduced from (24) 
 
 
After completing all forms, the variation can be submitted and sent to evaluation. 
At this point I could not make any change to the information submitted.  
University of Aveiro 
Health Sciences Department 
 
40  Curricular Internship Report 
  Raquel Pinela 
Besides the access to type I variations, the INFARMED, I.P.’s online application 
for type I variations electronic submission also accomplishes a database of 
SmPCs and PLs. These versions must be used whenever a new variation with 
impact on SmPC and/or PL is submitted and for MA renewal requests. This 
obligation is applicable to all nationally authorized products since November 2006 
(25). These versions available on INFARMED, I.P.’s online database have a 
special feature: all text changes and deviations from the approved version are 
registered as track-changes and it is not possible to unable this Microsoft Word’s 
functionally, as it can be observed in figure 15. 
 
 
Figure 15 – Example of INFARMED, I.P.’s track change file for product information texts 
 
Track-changes functionality is particularly important to INFARMED, I.P.’s variation 
managers, because it allows making an easy identification of the changes 
proposed and simultaneously avoid losing time comparing versions to find out if 
there are no other changes than those arising from the variation process.  
Regarding type I variations, the new information introduced on track-changes 
documents cannot present other than the one resulting from the variation itself. 
The adaptation of texts templates to the latest version of QRD recommendations 
should be avoided, since texts evaluation will not be performed by INFARMED, 
I.P.. Additionally, from January 1, 2012 all product information texts (SmPC, PL 
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and/or labelling) submitted during variation procedures should implement the 
necessary changes to correct the text accordingly to the rules of the new 
orthographic deal (26). 
 
Evaluation and Approval Timings 
Type IA variations of nationally authorized products will be assessed by the 
portuguese national competent authority, INFARMED, I.P., within 14 consecutive 
days after its submission. If INFARMED, I.P. does not emit any decision within this 
period, variations will be considered tacitly approved (15). 
On the other hand, type IB variations will be validated by INFARMED, I.P. within 5 
days of submission date. Only then the evaluation period will start and it can take 
up to 30 days. Thus, a type IB variation can be considered as tacitly approved if 
there is no decision from INFARMED, I.P. for a period of 35 consecutive days after 
submission (15). 
During the validation period INFARMED, I.P. will evaluate if the request complies 
with the applicable requirements. If nonconformities are detected, the applicant will 
be notified to complete or change the documentation submitted, so that the 
evaluation can proceed (15).  
During the evaluation period of a valid variation request INFARMED, I.P., may also 
ask for the presentation of additional documentation in order to perform a more 
complete evaluation of the request. The new documentation should be present 
within the period established by INFARMED, I.P. (15).  
The countdown for issuing decisions and tacit approval will be stopped from the 
day new documentation or information is requested, until its submission (15). In 
this context, it is very important to answer these element requests as soon as 
possible, so that the predicted date of approval is not too delayed. To accomplish 
this objective I used to include this type of task on my top priorities, unless 
otherwise indicated by MMD’s coordinator.  
Additionally, variation requests will be refused if the requested information is not 
submit within the define deadlines (15). In these situations the applicant can 
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submit a new request considering the correction of the points that lead to a 
negative position from the authority.  
 
Personal Experience: Modus Operandi and Principal Handicaps  
During the 9 months internship, I prepared, submitted and made follow-up of 
approximately 34 different type I variations, as presented on table 2.  
 
Table 2 - List of type I variation prepared and submitted during the internship 
 
 
Variation 
Identification 
Number 
Variation Description 
Variation 
type 
Estimated 
number of 
variation projects 
during internship 
2 
Change in the name of the medicinal 
product 
IB 6 
5 
Change in the name and/or address of a 
manufacturer of the 
finished product 
IA 1 
7 a) 
Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the finished 
product - Secondary packaging for all 
types of pharmaceutical forms 
IA 1 
7 b) 1. 
Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the finished 
product - Primary packaging site - Solid 
pharmaceutical forms, e.g. tablets and 
capsules 
IA 1 
7 c) 
Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the finished 
product - All other manufacturing 
operations except batch release 
IB 1 
8 b) 2 
Change to batch release arrangements 
and quality control testing of 
the finished product - Replacement or 
addition of a manufacturer responsible 
for batch release - Including batch 
control/testing 
IA 1 
9 
Deletion of any manufacturing site 
(including for an active 
IA 3 
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substance, intermediate or finished 
product, packaging site, 
manufacturer responsible for batch 
release, site where batch control 
takes place) 
15 a) 
Submission of a new or updated 
European Pharmacopoeia certificate of 
suitability for an active substance or 
starting material/reagent/intermediate 
in the manufacturing process of the 
active substance - From a manufacturer 
currently approved 
IA 1 
15 b) 2. 
Submission of a new or updated 
European Pharmacopoeia certificate of 
suitability for an active substance or 
starting material/reagent/intermediate 
in the manufacturing process of the 
active substance - From a new 
manufacturer (replacement or addition) 
IA 1 
29 a ) 
Change in the qualitative and/or 
quantitative composition of the 
immediate packaging material - All other 
pharmaceutical forms 
IA 1 
30 b) 
Change (replacement, addition or 
deletion) in supplier of packaging 
components or devices (when 
mentioned in the dossier); spacer 
devices for metered dose inhalers are 
excluded - Replacement or addition of a 
supplier 
IB 9 
40 b) 
Change of dimensions of tablets, 
capsules, suppositories or pessaries 
without change in qualitative or 
quantitative composition and mean mass 
- All other tablets, capsules, 
suppositories and pessaries 
IA 1 
42 a) 1. 
Change in: the shelf life of the finished 
product – as packaged for sale 
IB 3 
44 
Change in the summary of product 
characteristics of an essentially similar 
product following a Commission Decision 
for a referral for an original medicinal 
product in accordance with Article 30 of 
Directive 2001/83/EC 
IB 4 
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I consider important to outstand that for each type I variation identified on table 2, I 
had to follow all the requirements and procedures previously described, such as 
the preparation of documentation set, operating the INFARMED, I.P.'s online 
application for type I variations electronic submission, or answer to elements 
requests within the defined deadlines.  
In general, the best method to start preparing a type I variation is to identify the 
feasible variation at the guidance note. After that it is important to make sure that 
all the conditions mentioned for the chosen variation are integrally respected. If so, 
it is then possible to start collecting and preparing all the documentation previously 
enumerated.  
Notwithstanding the obligation to use the track-changes files for every variation of 
nationally authorised products, I should identify which file to use, because the 
version available at INFARMED, I.P.’s variations online application may not be the 
latest version in use. This important detail can be explained by the fact that new 
product information texts will be approved (i.e., stamped with INFARMED, I.P.’s 
approval imprint) only in case of type II variations or/and renewal processes. For 
all the other situations the changes made to the product information texts are 
approved and the new versions can be printed and normally used, however 
INFARMED, I.P. will not present new imprinted versions. As a consequence the 
versions available at Infomed (the portuguese database of medicines) and at 
INFARMED, I.P.’s online application for variations submission will remain the 
same until texts are fully evaluated and stamped with INFARMED, I.P.’s approval 
imprint.  
The presented features may, in some cases, difficult the identification of the latest 
version of the SmPC and PL which embraces all the information referent to 
previously submitted type I variations. In this context, I established a sequence of 
steps to be followed in order to detect the latest SmPC and/or PL: 
1. Identify the latest variations which had impact on product information texts. 
2. Verify if the product information texts submitted on each variation, reflect all 
the previous variations.  
3. If it is concluded that all the previous variations are reflected on the latest 
versions submitted, that documents can be used and the changes reflecting 
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the current variation should be included. On the contrary, if it is found out 
that the latest version submitted does not reflect all the variations previously 
submitted, the version under development should be drawn up to embrace 
all the changes on a single document, including those that did not result 
from the variation to be submitted.  
 
After submission, MA variation projects are in standby until there is an information 
request from INFARMED, I.P. or until the evaluation deadline is completed and 
tacit approval is granted. However, it is important to take in consideration that the 
end of the evaluation period does not necessarily represent the close out of the 
project. It is common that INFARMED, I.P. does not update the status of MA 
variation at the online application for type I variations electronic submission. In 
these situations I had to call to Direcção de Avaliação de Medicamentos (DAM), 
within the attendance periods (Tuesdays and Thursdays morning), to speak with 
INFARMED, I.P.´s manager responsible for the variation, in order to request the 
change of variation status to “Finalizado”. 
At this point, and in respect to Phagecon’s usual procedures, I should make a print 
screen of the INFARMED, I.P.’s online application for type I variations electronic 
submission and archive it at the MA variation specific folder. This print screen 
works as proof of evaluation and authorisation from INFARMED, I.P., since 
approval certificates are not emitted for the most of type I variations. The status of 
project at Phagecon’s Project Manager Software should also be updated and a 
notice notification should be prepared to inform client of the conclusion of the 
project. For medicines whose MAH is a company from the group (Laboratórios 
Basi, Overpharma, FHC, Empipharma or Paracélcia) variation history and their 
resulting documents should be updated on an online database named Online 
Regulatory Information on Medicines (ORIMED). ORIMED is a tool for internal 
management of regulatory information of each medicine and also a platform of 
interaction with the client, who access a restricted area through the clients’ portal. 
After gathering type I variation approval and if MA dossier is in e-CTD format, I 
should update the dossier on the e-CTD programme by the creation of a new 
sequence concerning a single variation. After validation, the new sequence shall 
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be recorded in non-rewritable CD-ROM and sent to INFARMED, I.P.. Since the 
variation is already approved, the information sent to INFARMED, I.P. is merely 
informative and no changes to the variation status will be possible.  
At last, regarding referral procedures, I would like to highlight a particular case, 
due to the specificity and usualness of the processes required by the respective 
EC decision. Despite the usual changes to SmPC and PL, the EC Decision of 
nimesulide referral procedure also encompasses a communication to healthcare 
professionals, as described on its Annex IV – “Conditions of the marketing 
authorisations”, which is presented on figure 16. 
 
 
Figure 16 – Example of Annex IV of an EC Recommendation regarding a referral procedure: the 
nimesulide case, adapted from reference (27)  
 
Thus, each MAH of medicines containing nimesulide had to send thousands of 
letters (approximate 10.000 just for Portugal) to inform certain specialized 
healthcare professionals of the removal of painful osteoarthritis indication, new 
posology and contraindications (28). In reality, the compliance with this safety 
measure required a big logistic effort at Phagecon’s and the enrolment of all the 
team so that the deadline could be accomplished. As a team, we started by 
organizing the different information letters from each of 12 MAHs in groups. After 
that we had to put each group of 12 notification letters on individual envelopes. 
The next step of work chain was pasting stickers with each healthcare professional 
name and address in all envelopes. The last task was to separate envelopes by 
the ZIP codes of the addresses on the stickers, so that this unusual volume of mail 
can be easily delivered on mail post. 
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Type II Variations 
Overall Requirements 
Any variation not specified in the guidance note for type I variations or that does 
not respect 1 or several conditions, should be classified as a type II variation (29).  
Similarly to type I variations, there is also a board-spectrum set of documentation 
which I had to prepare in order to submit type II variations, including (15): 
 Data supporting the request variation. 
 Any document for which a new version had to be prepared as consequence 
of the proposed variation, including MA dossier updated sections and 
SmPC, RCM and/or labelling. 
 Updated reports or experts evaluation of the proposed variation. 
 Proof of payment of the applicable fees and the corresponding guide of 
payment duly completed. 
 Identification of other MA variations already presented or to be presented in 
a near future, related to the same MA.  
 Presentation of the deadline for the implementation of the proposed 
measures, specifically for safety variations. 
 
Some of the information previously enumerated is requested to be presented in a 
specific form that should be completed and submitted for each type II variation. 
The referred form is applicable for nationally authorized products type II variations, 
and also for MRP and DCP approved products.  
Similarly to type I variations, SmPC, PL and labelling documents must be 
submitted in INFARMED, I.P.’s track-changes versions. However, type II variations 
allow MAH to adapt SmPC and PL templates to the latest QRD versions. Track-
changes from already approved variations should also be submitted and the new 
orthographic deal implemented (26). 
There is a specific type II variation which is requested by INFARMED, I.P. and 
intends to update SmPC and PL as a mitigation measure of a potential risk or 
safety issue. These variations are commonly noun as type II safety variations and 
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are communicated to MAH trough a notification letter from “Direcção de Gestão do 
Risco de Medicamentos” (DGRM), similar to the excerpt presented on figure 17. 
DGRM is one of the INFARMED, I.P.´s specialized department specialized on the 
evaluation and minimisation medicines’ risks.  
 
Figure 17 – Example of DGRM's notification letter, where PhVWP corresponds to 
Pharmacovigilance Working Party and RCM/FI to SmPC/PL 
 
The notification letter is usually directed to the pharmacovigilance responsible 
person and encompasses the identification of: 
 Medicines affected by the request. 
 Text changes to be implemented. 
 Deadline for implementation and variation submission. 
 Deadline for implementation of approved changes to the texts. 
 
Submission to INFARMED, I.P. 
All documentations related to MA type II variations should be submitted in 
electronic format. However, there are different submission processes on whether it 
is a common type II variation or a safety type II variation.  
Therefore, whenever considering the submission of common type II variations, I 
should sent a registered correspondence to INFARMED, I.P.’s address, with the 
following components (30): 
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 2 copies of documentation in electronic format (2 non-rewritable CD-
ROMs).  
 A requirement, in paper. 
 The original and signed version of application form duly signed.  
 
Every time an elements request is made during the validation process, all the 
information should be submitted in 2 new copies. However, if there is an elements 
request during the evaluation process, applicant shall submit only the information 
corresponding to the question received (30).  
Furthermore, I should have in consideration that any CD-ROM sent to INFARMED, 
I.P. must be properly identified with (30):  
 Medicine’s name, dosage and pharmaceutical form. 
 Applicant and MAH (if not the same). 
 Variation type and identification of the request nature (initial request, 
answer to elements request).  
 
To respect this last INFARMED, I.P. demand, I used to request CD-ROMs’ covers 
preparation to the administrative department (AD). Thus, all the information 
considered necessary for the identification of CD-ROM was directly printed on 
each CD-ROM by the use of a specific printer. To avoid confounding CD-ROMs 
from different projects I preferred to record the documentation only after receiving 
the CD-ROM with the printed cover.  
CD-ROMs content also has a proper organization that should be respected, in 
order to harmonize the disposition of information that is receive by INFARMED, 
I.P. and consequently raise evaluation efficacy rates (30). Thus, there are 2 folders 
that should be present on the opening of CD-ROM: “Dossier de Gestão” and 
“Dossier da AIM”. 
“Dossier da AIM” folder shall respect the CTD format, which will be analysed in 
detail on MA Renewals subsection of the present report. However, when 
considering type II variations, it is not necessary to prepare all CTD folders, but 
University of Aveiro 
Health Sciences Department 
 
50  Curricular Internship Report 
  Raquel Pinela 
rather only those affected by variation. In case MA dossier is in e-CTD format, the 
information should be submitted in the form of a new sequence. The validation 
reports of each sequence should also be recorded on the CD-ROMs. 
On its turn, “Dossier de Gestão” encompasses all administrative documentation 
related to the variation, such as requirement, copy of DGRM’s notification letter, 
proof of payment of applicable fees and the corresponding guide of payment duly 
completed or the variations form duly completed and signed. 
On the other hand, since May 25, 2009, safety type II variations submission 
process must be done through an online application (31). This online application is 
very similar to the one already presented for type I variations. In this context, it will 
be presented a list of major differences trough the different process phases or 
statuses, rather than a detailed description of the application functionalities, as 
following: 
 Requested – the variation is created by INFARMED, I.P. and not by 
applicant, who is limited to required documents upload and submission 
(32).  
 Payment confirmation – Applicable fees payment is not made prior to 
submission. After complete all the forms and upload the necessary 
documents, I must request the emission of a bill note. At this point the 
process will be blocked, i.e. no more changes can be done either to the 
forms or to the documents uploaded. The bill note identifies the fee value to 
be paid, as well as a specific identification number that must be present on 
the descriptive of bank transfer. A single bill note should be requested for 
each medicine. After requesting bank transfer to MAH and obtaining the 
respective proof of bank transfer, I should confirm the payment on the 
online application (32), as it is highlighted in figure 18. 
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Figure 18 – Bill note request at INFARMED, I.P.’s online application for safety type II variations, 
adapted from reference (32) 
 
 Payment validation – at this point INFARMED, I.P.’s accountability 
department will verify if the payment done is accordingly to the bill note. If 
everything is correct the variation status will change to “Pagamento 
Validado”. After this, the variation is eligible to evaluation by DGRM’s 
experts (32).  
 
Evaluation and Approval Timings 
Generally there are no defined timings for type II variations evaluation and 
approval. The exception is made for safety type II variations, which deadline for 
evaluation is usually present on the notification letter sent to MAH. 
Regardless the different deadlines for evaluation, at the end of this process MAH 
will receive an approval letter which authorizes the proposed MA variations.  
In case the variation comprised new product information texts, INFARMED, I.P. 
will present a new imprint version and update the versions available on Infomed 
and on type I variations online application.   
During the evaluation process, element requests may be considered necessary by 
the DGRM expert responsible for evaluation. A deadline of 30 working days is 
given to answer the 1st elements request and a 2nd elements request can be 
answered within 10 working-days. Only the 1st elements request deadline can be 
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extended. Whenever considering safety type II variations, elements requests 
should also be answered through the online application, as indicated in figure 19. 
 
 
Figure 19 – Answer to element request at INFARMED, I.P.’s online application for safety type II 
variations, adapted from reference (32) 
 
 
Personal Experience: Modus Operandi and Principal Handicaps  
During the 9 months internship, I prepared, submitted and made follow-up of 2 
type II variations and 3 safety type II variations.  
Since there are substantial differences between safety type II variations and 
common type II variations that don not allow describing my personal experience in 
type II variations as a whole. 
Therefore, and regarding the common type II variations preparation, the main 
hurdles were related to the definition of the documentation that should be 
submitted. Contrarily to type I variations there are no lists of document that shall 
be submitted. Thus, I had to think about the essential information for variation 
approval on a case by case basis. At this point, it was very useful for me to look at 
the most similar type I variation, because the documents listed on the guidance 
note are very likely considered essential for evaluation of type II variation and will 
have to be part of the documentation set submitted to INFARMED, I.P..  
In which concerns to safety type II variations, there are no major difficulties to be 
pointed since the documentation to be submitted is predefined and the online 
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application to be used for submission is user friendly, making the submission 
process simple and institutive.  
However there is one difficulty which cross-cuts all variation types (including type I, 
type II and safety type II) and even renewals: the identification of the latest version 
of the SmPC and PL, i.e. the version that embraces all the information referent to 
previously submitted variations, as previously explained on type I variations 
subsection. The reasons that explain this hardness, as well as mitigation 
strategies, were already discussed on type I variation subsection.  
A type II variation project will be considered finalized after the reception of the 
approval letter from INFARMED, I.P.. After that, in respect of Phagecon’s internal 
procedures, I should: 
 Update the project status at Phagecon’s online Project Manager Software.  
 Prepare a notice notification to inform client of the conclusion of the project.  
 Filed the original approval letter on the management dossier of the 
corresponding medicine and its scan on the electronic database, more 
specifically at the folder corresponding to the undertaken variations, 
existent at medicine’s specific folder. 
 Update medicine’s variation history at ORIMED, in case MAH is a company 
from the group.  
 
 
Transfer of Marketing Authorisation  
Overall Requirements 
Accordingly to EMA’s definition a transfer of MA “is the procedure by which the MA 
is transferred from the currently approved MAH to a new one, who is a different 
person/legal entity” (33). 
The request must be submitted by the current MAH and it should include all the 
following documents (15, 29): 
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 Document which identifies the medicine, the MA procedure number and the 
date MA was granted. Additionally other information considered relevant to 
medicines characterization, such as active substance, pharmaceutical form, 
registration number or dosage, may be added. 
 Document which identifies the current MAH and the proposed MAH, 
including for each one the following information: name, address, contact 
person at the indicated address, telephone number and e-mail.  
 A declaration certifying that the medicines’ up-dated process and MA 
dossier will be given to the future MAH. 
 A declaration stating the date from which the new MAH will assumed all 
responsibilities related to the medicine. 
 Document with the identification and detail contacts of the future 
responsible for medicine’s Pharmacovigilance activities. The signed and 
dated CV of the technical responsible for Pharmacovigilance should be 
annexed to the present declaration. 
 Document with the identification and detail contacts of the future 
responsible for the scientific department and activities. 
 Updated versions of SmPC, PL and labelling, with track changes.  
 Declaration that assures that the only changes made to medicine’s 
information texts are those that result from transfer of MA.  
 Proof of payment of applicable fees and the corresponding guide of 
payment duly completed. 
It is important to take in consideration that all these declarations should be 
properly signed by the current and the future MAHs’ legal representatives.  
 
Submission to INFARMED, I.P. 
Submission to INFARMED, I.P. is made on a paper basis only. Thus, all original 
documents are organized and divided by cover pages in a single dossier.  
The complete dossier is then sent as registered correspondence to INFARMED, 
I.P.’s address.  
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Evaluation and Approval Timings 
INFARMED, I.P. will evaluate and emit a decision within 60 days of submission of 
a valid request (15). Thus, the process will be considered finalised after reception 
of INFARMED, I.P.’s approval letter and the new imprinted version of product 
information texts.  
After approval, I had to follow all the Phagecon’s internal procedures, previously 
describe for type I and type II variations. 
 
Personal Experience: Modus Operandi and Principal Handicaps  
During the 9 months internship, I had the opportunity to prepared and follow-up 6 
transfers of MA.  
At the moment of INFARMED, I.P.’s approval letter reception, I had to confirm all 
its content. If I detected any deviation, such as a wrong pharmaceutical form or 
dosage, I had to contact INFARMED, I.P.’s responsible manager, within 
attendance periods, to communicate the mistakes found and request a new 
approval letter with accurate information.  
In general, transfers of MA are simple processes, which I accomplished without 
major difficulties apart from the narrow execution period of some cases. 
Nevertheless concerning the current INFARMED, I.P.´s efforts to reduce 
bureaucracy and to develop friendly user electronic tools, I consider that MA 
transfer submission process could be update to a simpler and less administrative 
process, such as MA variations. In my opinion this could be easily done by the 
emission of a new “Circular Informativa” regarding the obligation of electronic 
submission in 2 non-rewritable CD-ROMs, despite the current dossier in paper 
format. 
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Marketing Authorization Renewals 
Overall Requirements 
All medicines under commercialization in EU must have a valid MA, granted by a 
european competent authority. However this authorization is usually granted for a 
certain period of time, after which MAH should submit a renewal request, if there is 
intention to continue to commercialize the medicine.  
This section will give further details on MA renewal procedures for nationally 
authorized products, with special emphasis on the regulatory framework, the 
concert action and tasks to be performed and finally the major learning’s and 
greatest hurdles I felt. 
It should be noticed that, during the internship all the renewal projects that I had 
the opportunity to develop were from nationally authorized products, as a result, all 
the information to be present on this subsection is exclusively related to nationally 
authorized products and the applicable legislation for that period (August 2011 to 
May 2012).   
The first MA granted to a certain medicine is valid for a period of 5 years. After 
that, and if there is interest in maintaining the medicine on the market, a renewal 
request should be submitted within the established timelines (15). 
If the renewal request is approved, the second MA will be valid for an 
undetermined period, unless there are safety concerns that compel INFARMED, 
I.P. to define a new 5 years deadline for MA validity (15). This is particularly 
common in case of innovative medicines, which safety and/or efficacy profiles are 
not well noun.  
Apart from the particularities of each MA renewal request, there is a set of 
documentation and information that I had to prepare for each renewal I submitted, 
namely (15, 34): 
  A consolidated version of MA dossier, regarding safety, quality and 
efficacy. This consolidated version should include all changes introduced by 
all variations submitted and approved since the first MA. 
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 A description of medicine’s pharmacovigilance relevant data, presented on 
a Periodic Safety Up-date Report (PSUR), specially prepared for the 
renewal purposes. 
 Whenever applicable, any additional documentation that demonstrates the 
adaptation of medicine’s related procedures (e.g. manufacturing) to 
scientific and technical advances. 
 A set of relevant administrative information, such as: requirement, proof of 
payment of applicable fees and the corresponding guide of payment duly 
completed; renewal form; quality and clinical experts declarations; Good 
Manufacturing Practices (GMP); among others. 
 
All these required documents must be presented accordingly to a well-established, 
which is based on 4 initial folders: “Módulo 1”; “Módulo 2”; “Módulo 5” and “Dossier 
da AIM”, as it is presented on figure 20. 
 
 
 
Figure 20 – MA renewal request: folder organization within submission CD-ROM 
 
Inside “Módulo 1” folder there is also a highly structured organization for 
administrative documents disposal, which can be analysed in detail in figure 21. 
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Figure 21 – MA renewal request: folder organization within "Módulo 1", adapted from reference 
(35) 
 
There are several sub-folders of “Módulo 1”, which deserve to be further analysed, 
such as section 1.2.7, where GMP certificates for all manufactures mentioned on 
MA dossier and renewal form (36). GMPs are not mandatory for active substance 
manufacturers, but whenever available they should be present on this section as 
well.   
Regarding section 1.3.1.1, only the approved versions of SmPC, PL and labelling, 
i.e. those that have the INFARMED, I.P.’s imprint, should be considered. If it is not 
possible to have these documents with the referred imprint, a declaration should 
be added on this section. The declaration intends to confirm that, despite the 
absence of INFARMED, I.P.’s imprint, the approved and on use versions are those 
submitted in this folder.  
On the other hand, the preparation of section 1.3.1.2 involves the development of 
new SmPC, PL and labelling versions, encompassing all the information from 
previously submitted and already approved or still under evaluation variations, 
which had impact on product information texts, as well as the latest QRD 
suggestions. As previously described on MA variations subsection, SmPC and PL 
are to be prepared on the track-changes documents. 
Figure 22 presents the organizational structure of “Módulo 2” and “Módulo 5”, 
which are in fact very simple, since it only embraces a couple of folders.  
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Figure 22 – MA renewal request: folder organization within "Módulo 2" and "Módulo 5", adapted 
from reference (35) 
 
Quality and clinical experts declarations included on “Módulo 2” should respect the 
defined standards. Thus, quality expert’s declaration should (37): 
 Confirm that MAH respects the depositions of Decreto-Lei 176/2006, de 30 
de Agosto, in which concerns to he/she obligation to track the scientific and 
technical progress of medicine’s manufacturing and control processes. 
 Assure that all quality related changes were introduced after the respective 
MA variation request approval by the competent authorities. 
 Guarantee that the medicine manufacture and control processes are in 
accordance with CHMP current quality guidelines.  
 Identify qualitative and quantitative composition of the medicine’s active 
substance(s) and excipients.  
 Confirm the currently approved active substance(s) and final product 
specifications.  
 
On its turn, clinical expert declaration should describe medicine´s benefit-risk 
balance, based on the PSUR data and others collected since MA concession or 
last renewal. New and relevant information should be highlighted (37). By the 
mean of this declaration, clinical expert should also confirm that (37): 
 There are no new data, both clinical and/or non-clinical, that could change 
benefit-risk evaluation.  
 Medicine’s MA can be renewed with safety. If the expert has a different 
opinion he/she should provide a justification and recommend safety 
measures accordingly.  
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 Competent authorities have been informed about any new and significant 
data to medicines benefit-risk evaluation. 
 
On the other hand, “Módulo 5” is even simpler, since it will have a single 
document: the renewal PSUR. It is important to have in consideration that PSUR 
reporting period should match the renewal period. PSUR format and contents 
should respect the dispositions of Volume 9A – Pharmacovigilance for Medicinal 
Products for Human Use (the guidance in effect during the internship period) (36). 
No further details will be given on this particular matter because PSURs’ 
preparation was not part of mine internship activities.  
Finally regarding MA Dossier (“Dossier da AIM”), the first point to mention is that it 
should respect CTD format, either electronic (e-CTD) or note (folder structure). To 
avoid losing time preparing all folders and subfolders structure, MAH can 
download an empty CTD structure, as depicted from figure 23, from INFARMED, 
I.P.’s website.  
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Figure 23 – MA renewal request: CTD folder structure for Module 3 of MA dossier 
 
If there is more than one active substance manufacturer or more than one final 
product manufacturer, MAH can create more than one 3.2.S. or 3.2.P folders and 
identify them with the name of the corresponding manufacturer. It is important to 
notice that even with the duplication of these two folders their internal structure 
must be respect.  
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Submission to INFARMED, I.P. 
As a way to ensure that all documentation essential for renewal request validation 
is submitted, it is sensible to read the INFARMED, I.P.’s check-list for renewal 
requests. In case missing documents are detected, they should be added before 
submission (36). 
Renewal request submission must be done at least 180 days before the end of MA 
validity date, which is stated on MA certificated issued by INFARMED, I.P., as 
depicted from figure 24. It is important to take in consideration that this countdown 
will not start at expiry date stated on MA certificate, but rather on the day before 
that.  
 
 
Figure 24 – MA renewal request: example of MA certificate emitted by INFARMED, I.P.  
 
In case INFARMED, I.P. is closed on the day of renewal submission deadline, the 
request can be delivered the next working day.  
If renewal request is not presented within the defined timelines as previously 
indicated, MA will expire. Furthermore, no extensions to the deadline for renewal 
procedures submission will be conceded (36, 38). 
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The renewal request must be submitted by mail to INFARMED, I.P.’s address and 
to the care of Direcção de Avaliação de Medicamentos – Unidade de Manutenção 
no Mercado (DAM-UMM). It should be presented on 3 non-rewritable CD-ROMs. 
The folders recorded on CD-ROMs have to respect the well-established 
organization, previously described (36). 
Moreover, whenever preparing a MA renewal request submission I should had in 
consideration that any CD-ROM sent to INFARMED, I.P. must be properly 
identified with (36):  
 Medicine’s name, dosage and pharmaceutical form. 
 Applicant and MAH (if not the same). 
 Identification of procedure type (Renewal) and the submission date. 
 
As previously described to type II variations, I used to request the CD-ROM cover 
preparation, i.e. the printing of the essential information, to AD.  
 
Evaluation and Approval Timings 
After submission, MAH will be informed via e-mail of the validation of their renewal 
request, as well as of the responsible project manager at INFARMED, I.P. (34, 
37). 
However, if it is detected that the request has missing documents or documents 
with lack of compliance to applicable legislations, INFARMED, I.P. will emit a 
single elements request – validation elements request. MAH will have 20 days to 
answer this elements request and deadline extensions will not be conceded by 
INFARMED, I.P. (36, 38). If MAH does not respond or if the response is 
considered unsatisfactory, a preliminary hearing will be schedule. During the 
preliminary hearing it will be possible to add new documents. If at this point MAH’s 
answers still considered unsatisfactory or if preliminary hearing deadlines are not 
respected, MA revocation will be declared (34, 37). MAH will have 90 days to 
remove the affected medicine from the market. The 90 days countdown may start 
the day MA validity expires or any other date defined on INFARMED, I.P.’s 
revocation decision (36). 
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Every time an elements request requiring changes to submitted dossier is made 
during the validation process, all the information should be submitted in 3 new 
copies (36).  
After renewal request validation, INFARMED, I.P.’s responsible manager will start 
the evaluation process based on risk-benefit relationship, in order to determine if 
the balance remains positive. During the evaluation phase MAH will have 30 
working days to answer to a possible 1st elements request and 10 working days to 
answer a 2nd. MAH can ask for an extension of these deadlines twice, however the 
time deadline for 1st extension will not be superior to 30 or 10 working days, 
depending on whether it is related to the 1st elements request or the 2nd, 
respectively. In case it is necessary to ask for a 2nd extension request (at the end 
of 1st extension deadline), the extra time given cannot exceed half of the days 
conceded in the 1st extension (i.e., 15 or 5 working days) (36, 38).  
At the end of process’s evaluation, INFARMED, I.P.’s decision will be notified to 
applicant. In the granted MA notification letter’s annexes it will be possible to found 
the approved versions of SmPC, PL and labelling with INFARMED, I.P.’s imprint.  
On the other hand, if INFARMED, I.P.’s concludes that the benefit-risk relationship 
is no longer positive, a new MA will not be conceded. MAH will have 10 or 90 days 
to remove its medicine from the market, depending on the reason that lead to MA 
withdrawn. Days countdown may start at day MA validity expires or any other date 
defined on INFARMED, I.P.’s revocation decision (36). 
 
Personal Experience: Modus Operandi and Principal Handicaps  
From all the projects I had the opportunity to participate or develop at Phagecon, 
MA renewal request were the more complex, either because of the nature of some 
of the tasks involved either due to the need of planning well in advance.  
Nevertheless, the experienced gained from the 5 MA renewal submissions I 
prepared and submitted, allowed me to gradually gain more experience and 
consequently the ability to work more independently.  
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In respect to the legislative framework (previously described) and Phagecon’s 
internal procedures, there is a set of tasks with defined timelines that I had to 
respect whenever preparing a renewal project.  
Thus, approximately 4 months before submission deadline, it is necessary to make 
a critical analysis of MA dossier and the variations submitted, in order to determine 
which sections need to be updated. Then I had to request the information 
necessary to make this update to the respective MAH.  
At this point the project will be in stand-by until there is an answer from MAH. 
When the requested information is finally received I should confirmed if it is only a 
recent version of the already approved dossier or if in fact it is different information 
that do not respect the approved MA dossier contents (e.g. a new specification 
test). If I found out that there it is non-approved information, I should notify MAH 
that a new variation process concerning this information should be submitted 
before renewal submission. If MAH agrees, I should prepare and submit the 
variation as soon as possible. This step is extremely important because MA 
renewals should be used to present information updates only (e.g. recent active 
substance analyses certificates), rather than opportunities to present different 
information not previously evaluated. 
The analysis of the set of received information also allowed determining if it would 
be necessary to make a second information request to MAH or not.  
Independently from the decision taken it is now possible and highly advisable, to 
start to consolidate MA dossier, considering not just the new information received 
but also the variations submitted. During this process, the section with higher level 
of changes was, generally, the “Módulo 3” - Quality. 
It may be useful to simultaneously request clinical and quality experts to prepare 
and send the respective declarations, in order to guarantee that these documents 
are made available on time.   
At last, I had to prepare the administrative modules (“Módulo 2”; “Módulo 3”; 
“Módulo 5”), including all the applicable form and its annexes. 
Despite the presentation of renewal related tasks as chronologic events it does not 
necessarily mean that they cannot be performed simultaneously. Indeed the 
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greater the number of tasks performed before renewal deadline is too close, the 
better.  
 
 
Multilingual Notifications 
Overall Requirements 
In some situations, MAH may have interest on the commercialization of the same 
medicine in several countries, trough big international wholesalers like FHC. This 
compels us to the ideal scenario: to have a single PL and labelled package 
containing all the official languages of countries where it is going to be 
commercialized, so that the same production line is established and used no 
matter the destination country.  
INFARMED, I.P. approves product information texts in portuguese, which should 
be used exactly as presented on the approved versions. Thus, if there is the 
intention to add a translation to other languages of the approved texts, it will be 
necessary to submit to INFARMED, I.P. a variation of labelling and PL not related 
to SmPC information. This type of variation is commonly noun as multilingual 
notification. 
The documents necessary to submit a multilingual notification to INFARMED, I.P. 
are: 
 Approved labelling and/or PL (QRD format). 
 Proposed labelling and/or PL with track changes (QRD format). 
 Proposed labelling and/or PL without track changes (clean version in QRD 
format). 
 Declaration ensuring the equivalence between the Portuguese version and 
its translations. 
 Final artworks of the proposed versions.  
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Submission to INFARMED, I.P. 
To submit a multilingual notification, MAH should send to INFARMED, I.P.’s 
address the paper versions of the previously identified documents.  
The proposed versions will be tacitly approved, if there is no INFARMED, I.P. 
decision within 90 days of its submission.  
 
Personal Experience: Modus Operandi and Principal Handicaps  
For the several multilingual notification projects received during the internship, the 
first step I took was to request a draft translation of the latest PL approved version 
to Phagecon’s translation expert.  
Simultaneously, I could start preparing the labelling QRD version, if not already 
available, and to analyse the sections to be updated, accordingly to QRD latest 
templates. I should also prepare the labelling translation in QRD format, with 
special attention to the standard terms and phrases that must be used.  
After the reception of PL translated version, I had to perform a technical validation, 
especially regarding QRD terms, clinical terms and standard terms, using Medical 
Dictionary and EDQM database, respectively. The revised version will be send to 
MAH for artworks development.  
The process will be in standby until artworks reception. Before submission, I had 
to analyse the artworks documents to confirm its contents and readability 
standards. If it is considered that mock-ups should suffer any alteration, the 
respective comments were introduced on the document and sent back to MAH. At 
the time of mock-ups’ second version reception, I used to do a new verification in 
order to ensure that all the comments were correctly implemented. This process 
could be repeated several times until the final version was achieved. When mock-
ups final version was available the process could be submitted to INFARMED, I.P.. 
As already described for other regulatory processes, after approval there is a set 
of tasks that should be accomplished, namely: Project Manager updating and 
project close-out, ORIMED update (whenever applicable), archive of 
documentation on the network, and communication to client of notification 
approval.  
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Veterinary Medicinal Products  
A VMP is defined by the applicable legislation as: “any substance or combination 
of substances presented as having properties for treating or preventing disease in 
animals; or any substance or combination of substances which may be used in or 
administered to animals with a view either to restoring, correcting or modifying 
physiological functions by exerting a pharmacological, immunological or metabolic 
action, or to making a medical diagnosis” (39). 
This chapter intends to describe all the VMP related activities that I developed 
during the first months of internship to a temporary client, who outsourced quality 
services to Phagecon. The main activities performed during this period were: MA 
renewals, MA variations, PSUR’s fees payment and mock-ups revision. 
 
 
Marketing Authorisation Renewals 
Overall Requirements  
Similarly to already the described for human medicines, no VMP shall be placed 
on the European market before a MA is granted by a recognized competent 
authority. This MA also has a validity of 5 years, after which MAH should submit a 
renewal request, if he intends to keep the medicine on the market. Also similarly to 
human medicines, once the MA renewal is granted it will be valid for an 
undetermined period of time, unless there are safety concerns that lead competent 
authorities to establish another 5 years period (40). 
MA renewal request should present the following documents/information (40): 
 Consolidated version of all new all documents and information regarding 
VMP’s quality, efficacy and safety and variations submitted since first MA.  
 Updated version of product information texts. 
 PSUR. 
 Whenever applicable, additional documents that proof the adaption to 
technical and scientific progresses. 
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 Proof of payment of the applicable fees. 
The renewal request cannot include any new variation. If a MA variation is 
considered necessary, it should be submitted accordingly to the applicable 
procedures.  
DVG may request at any time additional documentation, considered necessary to 
make an accurate judgment of benefit-risk balance(40). 
MA will expire, if the medicine is not commercialized for a period of three 
consecutive years. These 3 years count even if the medicine had never been 
commercialized after first MA was granted. A new counting will start whenever 
there is a MA transfer (40). 
 
Submission to Direcção-Geral de Veterinária 
The deadline for renewal request presentation is the same as for human 
medicines, i.e. at least 180 days before MA validity date which is indicated on MA 
approval letter.  
All the documentation should be submitted in electronic format, in CD-ROM or 
DVD. Exceptionally, the original versions of proof of payment of applicable fees, 
renewal form and requirement should also be submitted in paper format (41). 
The electronic support should be well identified with the following information (42): 
 Name of VMP and its target species, if essential to avoid confusion with 
other products. 
 Type of application (i.e., renewal). 
 MAH’s identification. 
 Version and the respective date. 
 If there is more than one support to identify them, such as 1/3, 2/3 and 3/3.  
The organization of files on CD-ROM followed the one proposed by the client and 
presented on figure 25.  
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Figure 25 – VPM MA renewal requests: CD-ROM folder organization 
 
 
“Parte_I” folder contains the renewal form duly completed and other relevant 
administrative documents, such as GMPs from manufacturers or experts’ 
declarations.  
On its turn, “Parte_II” should contain proof of payment of renewal fee. Finally 
“Parte_III” should present all the updated documentation that constitutes MA 
dossier.  
Files are usually submitted in PDF format, with exception to the proposed versions 
of VMP information texts, which are prepared in word format. These documents 
should respect QRD format and present any change to the approved version on 
the track-change format, despite the fact that there is no specific document with 
this functionality, such it was described for human medicines. The clean version, 
i.e. without track-changes should also be presented (41).  
For both submission and answer to elements request only 1 copy is required (41).  
 
Evaluation and Approval Timings 
During MA renewal request assessment, competent authorities will determine 
whether the benefit-risk balance remains favourable. The final decision will be 
taken by DVG director-general, after considering Grupo de Avaliação de 
Medicamentos Veterinários (GAMV) opinion and position (40).  
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The decision will be reported to MAH within 120 days after submission of a valid 
request. The approval letter encompasses also the approved versions of VMP 
information texts (40).  
After renovation MA will be valid for an undetermined period of time, unless 
otherwise described on the approval letter. The obligation to submit a new renewal 
request within another 5 years will be assigned (40).  
At last, all the decisions will become public trough the publication on DGV’s 
website (43).  
 
Personal Experience: Modus Operandi and Principal Handicaps  
During the internship I had the opportunity to prepare and submit a single MA 
renewal, which MA dossier update was prepared by the client. Thus my 
responsibility was exclusively related to the administrative part of the process, 
which included: the preparation of the suggested files structure; the calculation of 
the applicable fees and their payment request and finally the submission to DGV 
by regular mail. 
In this context, the major difficulties were to correctly identify the fee that should be 
paid, as well as DGV’s submission requirements. The questions that could not be 
clarified trough the search on applicable legislation were asked directly to DVG via 
phone. Indeed, this was a very good solution, since all experts are extremely 
friendly and glad to help. 
 
 
Marketing Authorization Variations 
Overall Requirements  
MAH should request for an authorization whenever he wishes to introduce 
changes to the approved information, so that it is possible to guarantee that all 
activities are performed accordingly to the applicable legislation and the validated 
scientific methodologies (40). 
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This subsection intends to describe the procedures associated to VMP MA 
variations that I undertake during the first internship months. Most of the activities 
performed were related to documentation preparation, since the submission was 
completed by the client (MAH). 
Alike previously described for human medicines, MA variations of VMP are also 
classified, accordingly to their impact on the approved information, in: 
 Type IA. 
 Type IB. 
 Type II. 
 
The classification rules for national variation procedures, corresponding to those I 
developed during the internship, are detailed at DVG guidance “Normas referentes 
às alterações aos termos das autorizações de introdução no mercado por 
procedimento nacional” and at European guidance “Guideline on the details of the 
various categories of variations to the terms of marketing authorisations for 
medicinal products for human use and veterinary medicinal products”. 
European guidance also establishes different variations within each type and 
organizes them in 3 different categories (44): 
A. Administrative Changes 
B. Quality Changes 
C. Safety, Efficacy, Pharmacovigilance Changes.  
 
For each variation, the European guidance also identifies the conditions that 
should be respected and also the specific documents that should be submitted, as 
presented in figure 26. 
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Figure 26 – VPM MA variation requests: excerpt from european guidance on VMP MA variations 
classification 
 
Despite the need to present specific documentation to each type I variation, as 
outlined by European guidance, there is a general set of information that should be 
presented to DGV’s Director-general, including (40, 41): 
 Documents regarding the submitted variation, as well as the consequent 
updated version of MA dossier.  
 Comparative table with currently approved information and the proposed by 
the variation. A declaration assuring that no other changes have been done 
besides those identified on this table should be annexed. 
 Proof of payment of applicable fees. 
 Identification of other variations submitted and under DGV evaluation or to 
be submitted on a near future.  
 Updated versions of VMP information texts, whenever the variation has 
impact on them. 
 Variation form duly completed. 
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 Requirement directed to DGV’s director-general. 
 
In case of type IA variations, the implementation date should be presented (45).  
The applicable fees for type I variations and other VMP regulatory procedures are 
well described in portuguese law at “Portaria n.º 27/2011 de 10 de Janeiro”. This 
document should be consulted were calculating applicable fees, since there is no 
guide of payment as for human medicines.  
 
Submission to Direcção-Geral de Veterinária 
All the documentation should be submitted in electronic format, in CD-ROM or 
DVD. Exceptionally, the original versions of proof of payment of the applicable 
fees, variation form and requirement should also be submitted in paper format 
(41). 
The electronic support should be well identified with the following information (42): 
 Name of VMP and its target species, if essential to avoid confusion with 
other products. 
 Type of application (i.e., type IA variation or type IB variation and their 
respective identification number in accordance with European guidance). 
 MAH’s identification. 
 Version and the respective date. 
 If there is more than 1 electronic support, it will be necessary to identify 
each one of those, such as 1/3, 2/3 and 3/3.  
 
Files organization on CD-ROM followed the one proposed by the client and it is 
presented on figure 27.  
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Figure 27 – VMP’s MA variations CD-ROM structure: folder organization 
 
The “Anexo_I” folder should contain the variation form duly completed. On its turn 
“Anexo_II” should contain fee variation proof of payment of variation fees. And 
finally “Anexo_III” should present all documentation which supports the variation, 
as well as the updated versions of MA dossier, whenever applicable.  
Files are usually submitted in PDF format, with exception to the proposed versions 
of VMP information texts (whenever applicable), which are prepared in word 
format. All the changes made to the approved version of VMP information texts, 
should be presented as track changes. Additionally a clean version should also be 
submitted (41).  
Regarding the number of copies that should be submitted, it is important to have in 
consideration that they vary accordingly to the type of procedure. Thus, for type IA 
variations 1 electronic copy is enough. However, for type IB variations, 2 electronic 
copies should be submitted. Whenever there is an element request from the 
authority, the answer should be submitted in duplicate, i.e. 2 CD-ROMs or DVDs 
should be submitted (41). 
 
Evaluation and Approval Timings 
The approval or refusal of MA variations is emitted by DVG’s Director-general, 
after considering GAMV opinion. Minor type IA variations are an exception, since 
University of Aveiro 
Health Sciences Department 
 
76  Curricular Internship Report 
  Raquel Pinela 
they are usually not evaluated by GAMV, unless otherwise requested by Director-
general (43). 
In case of variation rejection or refusal, the reasons that lead to that decision will 
be properly identified and explained to MAH on the notification letter (45). 
The periods defined for evaluation of VMP type I variations are similar to those 
applicable to human medicines. Thus, a type IA variation will be evaluated by 
DGV’s Director-general within 14 days of its submission. If within this period there 
are no comments or emission of a variation refusal decision, it can be considered 
tacitly approved (40). It is important to notice that, despite the obligation to submit 
type IA variations, their implementation can be done even before the tacit approval 
(45). 
The same is not applicable to type IB variations, which can be considered tacitly 
approved, if within 30 days after its validation by DGV, DVG’s Director-general has 
not emitted a refusal communication (40). 
Variations concerning only changes to labelling and/or PL, which are not related to 
SmPC information, will be considered tacitly approved, if DGV does not request 
additional information or if a communication regarding variation refusal is not 
emitted within 30 days of its submission (43). 
The countdown for tacit approval is stopped whenever DVG requests for additional 
information or corrections to the documents previously submitted, such as product 
information texts. The variation request will be considered refused, if the applicant 
does not answer to DGV’s questions and appeals within 30 days (40). 
 
Personal Experience: Modus Operandi and Principal Handicaps  
The great majority of projects developed in this area did not require the 
preparation of variation support documentation, because they came finalized from 
the client. Additionally, several variation projects did not achieve the submission 
phase, because it was performed by the client. In this context of limited action, 
there were no major difficulties, since the activities carried out were very similar to 
the ones performed for human medicines’ variations projects. Some of the 
activities performed were: variation classification, the calculation of applicable fees 
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and the request of its payment by the client, the requirement preparation, or the 
update of VMP information texts.  
 
 
Periodic Safety Update Report’s Fees Payment 
Overall Requirements 
PSURs are documents intended to analyse the benefit-risk relationship of a VMP, 
based on knowledge acquire during the commercialization phase. They should 
encompass the worldwide safety information for a certain VMP, during a well-
defined period on time (46).  
The present section intends to describe the activities developed after PSURs 
submission, more specifically the contact with the competent authority and also 
the fee payment procedures. PSUR’s preparation and submission were not part of 
this internship’s activities.  
PSURs should mention all ADRs in animals and humans occurred both in EEA 
and third countries, which MAH become aware of. Special attention should be 
given to new information arisen during the period cover by PSUR (46).  
It is essential that PSURs encompass a scientific evaluation of benefit-risk 
balance, in order to determine if it remains positive or if there are new risks that 
require safety measures (40). 
PSUR should be updated and submitted periodically, accordingly the following 
predefined intervals (40): 
 Every six months since MA is granted until VMP commercialization. 
 Every six months during the first 2 years of commercialization. 
 Annually during the 3rd and 4th years of commercialization. 
 Whenever a renewal request is submitted. 
 Every 3 years after 1st renewal approval. 
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Additionally, PSUR should also be submitted whenever requested by the 
competent authorities.  
PSUR has a well-defined structured which should be totally respected. Further 
details on this topic can be consulted at DGV’s website (http://www.dgv.min-
agricultura.pt/portal/page/portal/DGV/genericos?generico=201325&cboui=201325)
, particularly at “Instruções de Elaboração de Relatórios Periódicos de Segurança” 
guidance document. 
 
Personal Experience: Modus Operandi and Principal Handicaps  
After receiving a new PSUR (directly submitted by the client) DVG sends an e-mail 
requesting the payment of the applicable fees.  
Based on this e-mail a sequence of tasks should be undertaken, in order to 
answer the competent authority request. These tasks are sequentially presented 
below: 
1. Determine fee value based on the analysis of “Portaria n.º 27/2011 de 10 
de Janeiro”. It is also useful to read the guidance “Taxas de Submissão de 
RPS de Medicamentos Veterinário Nacionais, de Reconhecimento Mútuo, 
Descentralizados ou do Projecto de Partilha (“WS”)”, available at DGV’s 
website, because it describes real examples of law application, so that it 
becomes easier to understand and to use.  
2. Sent payment request to the client, with clear identification of the value to 
be paid, the identity and the corresponding VMP and procedures.  
3. Reception of fee payment proof and data verification. 
4. Sent to DGV, via e-mail, the payment proof of applicable fees to the 
concerned PSUR.  
 
This was a very simple and mostly administrative activity that raised no issues.  
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National Monitor Plan for Veterinary Antimicrobial Consumption  
DGV prepares annually a plan for the control of VMP use in food-producing 
animals, in order to verify if the using conditions respect the applicable legislation 
(40).  
Lately there has been an increase of antimicrobial resistance in bacteria from 
animal production sites. This may lead to serious public health problems, leading 
EU to create the European Surveillance of Veterinary Antimicrobial Consumption 
(ESVAC), which intends to monitor veterinary antimicrobial consumption trends 
(47). 
In this context, regarding the analysis of antimicrobial consumption in Portugal, 
DGV requested to MAHs and retailers information regarding the sales volume for 
VMP containing antimicrobials on its compositions, trough notification letters 
similar to the one presented on figure 28. 
 
Figure 28 – DGV's notification letter for the submission of antimicrobial consumption in Portugal 
during 2010 
 
University of Aveiro 
Health Sciences Department 
 
80  Curricular Internship Report 
  Raquel Pinela 
The information should be introduced on a specific Excel document, depicted from 
figure 29, which was specifically developed by DGV for this purpose, allowing the 
standardisation of it presentation by different MAHs, which will contribute to an 
easier and more efficient analysis.  
Thus, the information regarding sales volume will be organized by medicine, in the 
first column, and by portuguese district, in the last column. The unique column of 
free answer is the one regarding the number of packages sold. 
 
 
 
Figure 29 – Excel sheet developed by DGV for harmonized presentation of antimicrobial data by 
the several MAHs 
 
This was another administrative task verify easy to performed. Nevertheless it was 
detected a mistake on DGV’s file, since one of the VMP commercialized by the 
client during 2010 was not available at the first column list of possibilities. This 
problem was communicated to DGV on the e-mail submitting the excel file and 
sales volume for that VMP was indicated on a single table.  
At this moment the report that analysis the collected information is already 
available for public consultation at DGV’s website (47).  
The conclusions on antimicrobial consumption trends will then be compared 
among members states (47).  
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Personal Experience: Modus Operandi and Principal Handicaps  
To accomplish this task I had to request the sales volume to the client, 
corresponding to those medicines market in Portugal and containing any 
antimicrobial agent.  
After receiving these data, the next step was their introduction on the Excel file. 
Despite being extremely time-consuming, this task did not raised any issue. 
 
 
Quality Review Documents and Mock-ups Revision 
Sporadically, the client requested the revision of VMP information texts and the 
implementation of several changes to QRD portuguese versions, in the context of 
referral procedures or information update.  
The revision of mock-ups was also requested and performed accordingly to QRD 
guidance and portuguese applicable legislation (Anexo II of Decreto-Lei n.º 
148/2008, de 29 de Julho). Figure 30 presents an example of mock-ups revision 
process, where it is possible to see several comments to be implemented on the 
original file.  
 
 
Figure 30 – Example of Veterinary Medical Product's mock-ups revision 
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Personal Experience: Modus Operandi and Principal Handicaps  
Mock-ups revision requires extreme concentration, so that the tiniest detail can be 
detected. It is also essential to keep in mind the legislation requirements regarding 
PL and labelling.  
This features turn out into long revisions, which can be extremely extending.  
In this, context I considered this tasks strenuous and time-consuming. A part from 
this no other difficulties were felt. 
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DISCUSSION
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This 9 months internship as RA officer was my first contact with employment 
environment. In the beginning, this was a very intimidating experience, because I 
could not know, if I was prepared to correspond to company’s expectations.  
An additional challenging factor of this internship was associated to its field, i.e. 
RA, which I had now concluded to be more demanding and stressful than other 
areas, such as the conduction of clinical studies, my current working area. This 
personal opinion is justified by the highly regulated environment associated to an 
enormous quantity of procedures, which are not referred in original law and 
regulation documents, but need to be integrally respected. 
The activities developed as a RA officer were focused on post-marketing phase of 
products lifecycle and encompassed as major tasks and responsibilities human 
medicines and VMPs MA’s management, always in compliance with the applicable 
legislation. From the analysis of my internship and all activities performed, it is 
possible to identify several of difficulties of transversal character. 
Thus, in general, I felt difficulty to get familiarized with the applicable legislation 
and requirements of each type of process. There is a lot of information in several 
documents types, such as: national laws, INFARMED, I.P. press releases, 
frequently asked questions, among others. The analysis and integration of all this 
information is an extremely complex and time-consuming process. However, it 
could not be left unsaid, that the hurdles regarding the adaption to legal framework 
were only overcome thanks to a strong support from my colleagues, especially 
from my coordinator Ricardo Andrade, who already has a strong and solid 
knowledge background. To optimize the knowledge acquired it was essential to 
put it into practice, trough the realization of all tasks required to conclude a certain 
regulatory process and achieve regulatory approval. With the continuous practice, 
trough the development of several similar projects, it was gradually easier to 
understand the tasks that should be performed and their specific timings and 
requirements.  
Another difficulty felt was related to time management. Sometimes it become 
particularly demanding to manage a big amount of simultaneous projects and 
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tasks may start accumulating. Phagecon offers quality scientific-consulting 
services to pharmaceutical industry, which implies to respect regulatory timelines 
and to deliver finalised projects on time. However, the workflow of a CRO can be 
very different from industry, since there are spontaneous requests by clients at any 
period of the year. In this context, it is not possible to predict future projects and 
organize them in a temporal manner that better feats working capacities.  
Clients’ recognition of Phagecon’s services and capacity to perform them on time 
is translated into a lot of new projects, almost every week. As a consequence 
there may be periods where each collaborator feels overloaded. To ensure that 
projects are finalised on time, it is essential to be aware of each project importance 
and urgency, as well as of the possibility to request a deadline extension. This 
information will allow establishing working priorities and diminishing personal 
stress. To better face this situation, I had to make an effort to adjust my working 
rhythm to the high-speed usually practiced at Phagecon and to spend extra 
working hours whenever necessary to accomplish goals. Time management and 
tasks prioritization, previously described, were also extremely important to deliver 
my projects on time. 
Despite the difficulties felt, I consider that they were mitigated allowing to positively 
overcome the internship challenge. The accomplishment of all the objectives 
initially defined is also proof of internship success, since it allowed to: 
• Develop depth knowledge on RA and medicines legal framework and the 
analytical capacity to understand and predict their impact on usually 
performed processes.  
• Become familiarized with the essential standards and processes that should 
be followed for obtaining regulatory approvals, and thereby to better 
understand the specific and realistic aspects of most commonly performed 
activities. 
• Strengthen personal skills such as organization and the capacity to handle 
several tasks and projects simultaneously and prioritize them, contributing 
to efficiently manage time and stress.  
• Contribute to the success of MMD’s projects and Phagecon’s goals. 
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Furthermore I can say that the initially defined goals to this internship were in fact 
overcome, because I was able to acquire knowledge and MA management 
experience regarding VMPs, which I initially did not predict or intended.  
I also would like to highlight that there were 2 essential factors that contributed to 
overcome the difficulties previously described and consequently to influence this 
positive balance of internship as RA officer. Among those factors there is the solid 
and very complete academic formation acquired during Biomedical Sciences 
degree and also Pharmaceutical Biomedicine master. The specificity of subjects 
discussed during the academic years gave me a strong background regarding 
scientific knowledge and also basic principles of legislative framework.  
The second factor was the support from all Phagecon’s colleagues, who largely 
contributed to the success of my internship. Their guidance and support were 
essential to accomplish projects’ goals and to fill in gaps on my knowledge.  
In short, I can say that the internship was an extremely important step forward in 
my professional career because it contributed for the acquisitions and/or 
development of essential technical and also interpersonal skills. A list of the 
acquired skills is presented below. 
 
Technical Skills 
 General knowledge of human medicines and VMP’s legal frameworks. 
 Knowledge of CTD structure and basic user of e-CTD. 
 Submission of national renewal processes, for both human medicines and 
VMPs. 
 Submission of national variation processes, for both human medicines and 
VMPs. 
 Ability to use INFARMED, I.P. online application regarding type I and type II 
variations. 
 Knowledge of QRD templates and readability requirements. 
 Preparation and revision of product information texts. 
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Interpersonal Skills 
 Time management.  
 Multitasking and high level of organization. 
 Responsibility sense.  
 Ability to work under stress and deadlines pressure. 
 Increased meticulousness and attention to the smallest details. 
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CONCLUSION 
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The experience as a RA officer at Phagecon was extremely rewarding, because it 
allowed the application, in real situations, of knowledge acquired during 
Biomedical Sciences degree and Pharmaceutical Biomedicine master. This 
contact with common RA projects and the opportunity to develop several tasks 
and activities within those projects, contributed not just for knowledge 
consolidation, but also for the acquisition of new competences, both technical and 
interpersonal.  
The combination of theoretical knowledge with long term practical training in a real 
enterprise environment gave me a top higher education and more confidence on 
my knowledge and working capacities. 
These features constitute a great competitive advantage in the current job market, 
since most of the recent graduates do not have any working experience on their 
education fields.  
This is particularly important in areas with highly structure legislative frameworks, 
such as RA, whose dominance requires a lot of study but also years of practice. 
Nevertheless, it is important to have in consideration that being a RA officer 
requires continuous learning and research. In other words the learning process will 
never be finished and it will continue to evolve as I gain more professional 
experience. 
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